Cited by 150Schizophrenia research and treatmentTreatment of Major DepressionTryptophan and brain disorders

The DOI matches its Crossref record, with a small difference in title or year; 26 of the 26 references it cites were found in a registry or an index.

Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study

Miyaoka, Tsuyoshi, Yasukawa, Rei, Yasuda, Hideaki, Hayashida, Maiko, Inagaki, Takuji, Horiguchi, Jun·2008·Clinical Neuropharmacology

DOI 10.1097/wnf.0b013e3181593d45

Open this paper in CoChat — free account

Abstract

Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase, and has been shown to delay disease in a mouse model of neuropsychiatric disorders. Recently, we reported the antipsychotic effects of minocycline in patients with schizophrenia. In a pilot investigation, we administered minocycline (150 mg/d) for 4 weeks as an open-label adjunct to antipsychotic medication to 22 patients with schizophrenia. The Positive and Negative Syndrome Scale for schizophrenia showed statistically significant and robust clinical improvements with minocycline treatment, which were maintained at follow-up evaluation 4 weeks after the end of minocycline treatment. There were no adverse events. These results suggest that minocycline may be a safe and effective adjunct to antipsychotic medications, and that augmentation with minocycline may prove to be a viable strategy for "boosting" antipsychotic efficacy and for treating schizophrenia.

Integrity signals

Registry

Crossref · 10.1097/wnf.0b013e3181593d45

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Microglia: Intrinsic immuneffector cell of the brain
Gehrmann, J., Matsumoto, Y., & Kreutzberg, G. W. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00015-h · Cited by 1,111
Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease
Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,060
A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window
Yrjänheikki, J., Kauppinen, T. M., Keinänen, R., Goldsteins, G., Chan, P. H., & Koıstınaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,040
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia
Tikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958
Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson’s Disease
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789
Minocycline Provides Neuroprotection Against N -Methyl- d -aspartate Neurotoxicity by Inhibiting Microglia
Tikka, T., & Koıstınaho, J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7527 · Cited by 539
The Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518

Show all 26 references

Research works printed but not linked: 1

German, 2004, Regulation of apoptosis by typical and atypical antipsychotics in rat frontal cortex., Eur Neuropsychopharmacol, 55, 214S

Sorted by citations

Items 101–150 of 150

A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study
Qurashi, I., Chaudhry, I. B., Khoso, A. B., Husain, M. O., Hafeez, D., Kiran, T., Lane, S., Naqvi, H., Minhas, F. A., Nizami, A. T., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.10.025 · Cited by 17
Unraveling the dual role of bilirubin in neurological Diseases: A Comprehensive exploration of its neuroprotective and neurotoxic effects
Kaur, A., Rohit, & Aran, K. R. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149472 · Cited by 17
Minocycline, a microglial inhibitor, reduces ‘honey trap’ risk in human economic exchange
Watabe, M., Kato, T. A., Tsuboi, S., Ishikawa, K., Hashiya, K., Monji, A., Utsumi, H., & Kanba, S. (2013) · Scientific Reports · doi:10.1038/srep01685 · Cited by 18
Lyme disease and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS): an overview
Rhee, H., & Cameron, D. J. (2012) · International Journal of General Medicine · doi:10.2147/ijgm.s24212 · Cited by 16
The effect of minocycline on indolamine 2, 3 dioxygenase expression and the levels of kynurenic acid and quinolinic acid in LPS-activated primary rat microglia
Bahrami, Z., Firouzi, M., Hashemi-monfared, A., Zahednasab, H., & Harirchian, M. H. (2017) · Cytokine · doi:10.1016/j.cyto.2017.12.013 · Cited by 15
Ameliorative effects of Fingolimod (FTY720) on microglial activation and psychosis-related behavior in short term cuprizone exposed mice
Li, S., Sakurai, K., Ohgidani, M., Kato, T. A., & Hikida, T. (2023) · Molecular Brain · doi:10.1186/s13041-023-01047-5 · Cited by 16
Metabolite abnormalities in psychosis risk: A meta-analysis of proton magnetic resonance spectroscopy studies
Wang, Y.-M., Xiao, Y., & Xie, W.-L. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102220 · Cited by 15
Drugs with glutamate-based mechanisms of action in psychiatry
Chrobak, A., & Siwek, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00656-8 · Cited by 11
Peripheral blood MicroRNAs as biomarkers of schizophrenia: expectations from a meta-analysis that combines deep learning methods
Han, S., Li, Y., & Gao, J. L. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2023.2258975 · Cited by 11
Activation of the Maternal Immune System as a Risk Factor for Neuropsychiatric Disorders
Smith, S. E. P., Hsiao, E. Y., & Patterson, P. H. (2010) · Springer eBooks · doi:10.1007/978-1-60327-921-5_7 · Cited by 12
Schizophrenia Aetiology and Drug Therapy: A Tale of Progressive Demystification and Strides in Management
Onaolapo, A. Y., & Onaolapo, O. J. (2018) · Advances in Pharmacology and Pharmacy · doi:10.13189/app.2018.060201 · Cited by 9
Minocycline as adjunct therapy for a male patient with deficit schizophrenia
Chen, X., Xiong, Z., Li, Z., Yang, Y., Zheng, Z., Li, Y., Xie, Y., & Li, Z. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s179658 · Cited by 9
Is it possible to prevent excessive synaptic pruning in schizophrenia? Possibilities and limitations
Pawlak, A., Stefanowicz, J., Kotkowska, Z., Gabryelska, A., Sochal, M., Napieraj, F., Kotlicka‐Antczak, M., & Strzelecki, D. (2025) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2025.1656232 · Cited by 9
Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT
Deakin, J. F. W., John Suckling, A., Dazzan, P., Joyce, E. M., Lawrie, S. M., Upthegrove, R., Husain, N., Chaudhry, I. B., Dunn, G., Jones, P. B., et al. (2019) · Efficacy and Mechanism Evaluation · doi:10.3310/eme06070 · Cited by 8
Synthesis and biological evaluation of novel flavanone derivatives as potential antipsychotic agents
Gu, H.-S., Chen, X., Zhang, J., Zhang, L., & Li, L. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12843 · Cited by 8
Minocycline for Schizophrenia: A critical review
Miyaoka, T. (2012) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2012.224056 · Cited by 8
Self-citation
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Bumb, J. M., Enning, F., & Leweke, F. M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660165 · Cited by 7
Abnormality of cerebral perfusion in the posterior cingulate gyrus of a refractory patient with schizophrenia and minocycline treatment
Hashimoto, K. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.021 · Cited by 7
Update on New and Emerging Treatments for Schizophrenia
Gopalakrishna, G., Ithman, M., & Lauriello, J. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.01.005 · Cited by 6
Lessons From Clinical Trials of Immunomodulatory Drugs in Psychiatric Disorders
Pak, T. K., Haque, N., & Jha, M. K. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.11.009 · Cited by 5
Minocycline and the risk of acute psychiatric events in adolescence: A self-controlled case series
Brauer, R., Herrero-Zazo, M., Barlow, D. J., Gaughran, F., Taylor, D. M., & Howard, L. M. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118821852 · Cited by 5
Reduction of plasma procoagulant activity in patients with schizophrenia during pharmacotherapy: thrombodynamic parameters of coagulation before and after treatment
Os, B., Karpova, N. S., Mi, F., Sizov, S. V., & Oleichik, I. V. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201911910151 · Cited by 5
Redox and Microglia in the Pathophysiology of Schizophrenia
Kato, T. A., Hyodo, F., Yamato, M., Utsumi, H., & Kanba, S. (2015) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.14-00235-4 · Cited by 5
Increased Lymphocyte Caspase-3 Activity in Patients with Schizophrenia
Lazarevic, D. S., Đorđević, V. V., Ćosić, V., Vlahović, P., Tošić-Golubović, S., Ristić, T., & Đorđević, V. B. (2010) · Journal of Medical Biochemistry · doi:10.2478/v10011-011-0002-x · Cited by 5
Herpes viruses and neuroinflammation: PET imaging and implication in schizophrenia
Doorduin, J. (2010) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 4
Neurodevelopmental and Neuropsychiatric Disorders
Monji, A., Maezawa, I., Mizoguchi, Y., Kato, T. A., & Jin, L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1429-6_14 · Cited by 4
Overactivation of Microglia as a Shared Pathophysiology in Different Neuropsychiatric Disorders
Eltokhi, A. (2024) · Integrated science · doi:10.1007/978-3-031-72079-6_11 · Cited by 3
The Psychotic Face of the Immune System: Inflammation and Schizophrenia
Meyer, U. (2013) · doi:10.1002/9781118314814.ch21 · Cited by 3
Melatonin and Other Neuroprotective Agents Target Molecular Mechanisms of Disease in Amyotrophic Lateral Sclerosis
Fotinos, A., Zhu, Y., Mao, L. L. J., Atassi, N., Zhou, E., Ahmad, S., Guan, Y., Berry, J. D., Cudkowicz, M., & Wang, X. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_51 · Cited by 2
Microglia inhibition rescues developmental hypofrontality in a mouse model of mental illnessPreprint
Chini, M., Lindemann, C., Pöpplau, J. A., Xu, X., Ahlbeck, J., Bitzenhofer, S. H., Mulert, C., & Hanganu‐Opatz, I. L. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/254656 · Cited by 2
Minocycline as an Evidence-Based Adjunct Treatment in Schizophrenia
Kelly, D. L., & Wehring, H. J. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180413-01 · Cited by 1
Some Noncommunicable Diseases of the Central Nervous System with a Possible Infectious Etiology (in Collaboration with V.A. Orlova, I.I. Mikhailova, A.A. Garbuzov, D.A. Khavkina, P.V. Chukhliaev, T.A. Ruzhentsova I. L. Naidenova, A. B. Danilov, A.V. Simonova, E.G. Filatova, I.A. Pavlovsky, O.V. Bystrova, A.M. Zatevalov, S.L. Bezrodny, T.Sh. Sadekov)
Zinserling, V. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-96260-9_20 · Cited by 1
The Magic Shotgun: Does It Fit the Clinician and Will It Point at Schizophrenia?
Mortimer, A. M. (2011) · Springer eBooks · doi:10.1007/978-94-007-0834-1_2 · Cited by 2
Investigating the mechanism by which the atypical antipsychotic clozapine reduces disease in experimental autoimmune encephalomyelitis
Zareie, P. (2017) · doi:10.26686/wgtn.17065139.v1 · Cited by 1
Microglial Abnormalities in the Pathophysiology of
Monji, S., Mizoguchi, Y., & Kato, T. A. (2014)
Quantitative Evaluation of Microglial Activation and Vascularization in Suicide
Schnieder, T. P. (2014) · CUNY Academic Works (City University of New York)
Mediators of neuroinflammation
Tikamdas, R., Zhang, P., & Liu, B. (2016) · Wiley eBooks · doi:10.1002/9781118832431.ch4
Neuroinflammation and psychosis; antipsychotic medication.
Bloomfield, P. S. (2015) · Spiral (Imperial College London) · doi:10.25560/39588
Trombodynamics Method in the Assessment of Coagulation Parameters in Psychopharmacotherapy of Endogenous Mental Disorders
Karpova, N. S., Os, B., Oleichik, I. V., Mi, F., Левченко, Н. С., Sizov, S. V., & Nikolaeva, E. R. (2020) · Psikhiatriya · doi:10.30629/2618-6667-2020-18-4-16-25
Investigating the mechanism by which the atypical antipsychotic clozapine reduces disease in experimental autoimmune encephalomyelitis
Zareie, P. (2017) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17065139 · Cited by 1
Tetracyclines
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01524-9
Faculty Opinions recommendation of The methodology of TSPO imaging with positron emission tomography.
Perani, D. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.730624735.793537458
Additional file 2 of Ameliorative effects of Fingolimod (FTY720) on microglial activation and psychosis-related behavior in short term cuprizone exposed mice
Li, S., Sakurai, K., Ohgidani, M., Kato, T. A., & Hikida, T. (2023) · Figshare · doi:10.6084/m9.figshare.23672669
Additional file 3 of Ameliorative effects of Fingolimod (FTY720) on microglial activation and psychosis-related behavior in short term cuprizone exposed mice
Li, S., Sakurai, K., Ohgidani, M., Kato, T. A., & Hikida, T. (2023) · Figshare · doi:10.6084/m9.figshare.23672672
Additional file 1 of Ameliorative effects of Fingolimod (FTY720) on microglial activation and psychosis-related behavior in short term cuprizone exposed mice
Li, S., Sakurai, K., Ohgidani, M., Kato, T. A., & Hikida, T. (2023) · Figshare · doi:10.6084/m9.figshare.23672666
Additional file 4 of Ameliorative effects of Fingolimod (FTY720) on microglial activation and psychosis-related behavior in short term cuprizone exposed mice
Li, S., Sakurai, K., Ohgidani, M., Kato, T. A., & Hikida, T. (2023) · Figshare · doi:10.6084/m9.figshare.23672675
Inflammation, infections et maladies mentales : identification de biomarqueurs et applications thérapeutiques potentielles
Fond, G. B. (2016) · theses.fr (ABES) · doi:10.70675/c6ecdda4z491cz4468zbdd6za65dbe62f0cb
Tetracycline antibiotics: Emerging roles in neuropsychiatric disorders
Acar, A. Ş., Saday, Ö., & Erbaş, O. (2024) · Demiroglu Science University Florence Nightingale Journal of Medicine · doi:10.5606/fng.btd.2024.149
BindingDB Entry 7886: Synthesis and biological evaluation of novel flavanone derivatives as potential antipsychotic agents.
BindingDB (2017) · UC San Diego · doi:10.7270/q2jw8cr0

Authors: Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J.
Affiliations: Shimane University (JP)
Corresponding author: Miyaoka, Tsuyoshi
ORCID: Miyaoka, Tsuyoshi
Hayashida, Maiko
Inagaki, Takuji
Horiguchi, Jun
Venue: Clinical Neuropharmacology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2008-09
Volume: 31
Issue: 5
Pages: 287-292
ISSN: 0362-5664 (ISSN-L)
DOI: 10.1097/wnf.0b013e3181593d45
OpenAlex: W2018922612
Cited by: 146
References: 26
Citations by year: 2026: 1 · 2025: 3 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 14 · 2017: 7 · 2016: 9 · 2015: 14 · 2014: 15 · 2013: 14 · 2012: 13
FWCI: 6.55
Type: journal article
Language: en
Open access: closed
Locations: Clinical Neuropharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: minocycline, schizophrenia, adjunctive therapy, antipsychotic augmentation, caspase inhibition, inducible nitric oxide synthase, antipsychotic efficacy
MeSH terms: Adult, Female, Follow-Up Studies, Humans, Male, Middle Aged, Minocycline, Pilot Projects, Schizophrenia, Schizophrenic Psychology, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks